ATE365584T1 - Verfahren und produkt zur transfektion mit genetischem material - Google Patents

Verfahren und produkt zur transfektion mit genetischem material

Info

Publication number
ATE365584T1
ATE365584T1 AT99901307T AT99901307T ATE365584T1 AT E365584 T1 ATE365584 T1 AT E365584T1 AT 99901307 T AT99901307 T AT 99901307T AT 99901307 T AT99901307 T AT 99901307T AT E365584 T1 ATE365584 T1 AT E365584T1
Authority
AT
Austria
Prior art keywords
genetic material
gene transfection
transfection
product
conjugated
Prior art date
Application number
AT99901307T
Other languages
English (en)
Inventor
Donald Tomalia
Lajos Balogh
Original Assignee
Dendritic Nanotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendritic Nanotechnologies Inc filed Critical Dendritic Nanotechnologies Inc
Application granted granted Critical
Publication of ATE365584T1 publication Critical patent/ATE365584T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/914—Protein engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99901307T 1998-01-07 1999-01-06 Verfahren und produkt zur transfektion mit genetischem material ATE365584T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7066698P 1998-01-07 1998-01-07

Publications (1)

Publication Number Publication Date
ATE365584T1 true ATE365584T1 (de) 2007-07-15

Family

ID=22096666

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99901307T ATE365584T1 (de) 1998-01-07 1999-01-06 Verfahren und produkt zur transfektion mit genetischem material

Country Status (7)

Country Link
US (1) US6475994B2 (de)
EP (1) EP1051244B1 (de)
JP (1) JP2002500033A (de)
AT (1) ATE365584T1 (de)
CA (1) CA2317666A1 (de)
DE (1) DE69936377D1 (de)
WO (1) WO1999034908A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146918A1 (en) * 2000-02-18 2004-07-29 Weiner Michael L. Hybrid nucleic acid assembly
WO2002000870A2 (en) * 2000-06-26 2002-01-03 Christian Plank Method for transfecting cells using a magnetic field
JP2005530517A (ja) * 2002-06-27 2005-10-13 ジョージア テック リサーチ コーポレイション ナノサイズ光学蛍光ラベルおよびその使用
US20040048260A1 (en) * 2002-09-10 2004-03-11 Fu-Hsiung Chang Transfection of nucleic acid
US20040138154A1 (en) 2003-01-13 2004-07-15 Lei Yu Solid surface for biomolecule delivery and high-throughput assay
US20070269891A9 (en) * 2003-01-13 2007-11-22 Yasunobu Tanaka Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells
DE60333435D1 (de) * 2003-02-03 2010-09-02 Bioware Technology Co Ltd Genpistole mit Niederdruckgasbeschleunigung
WO2004083450A2 (en) * 2003-03-21 2004-09-30 The General Hospital Corporation D/B/A Massachusetts General Hospital Hyperbranched dendron and methods of synthesis and use thereof
EP1648622A4 (de) * 2003-07-21 2009-11-11 Dendritic Nanotechnologies Inc Stabilisierte und chemisch funktionalisierte nanopartikel
WO2006078640A2 (en) 2005-01-19 2006-07-27 International Technology Center Alterations utilizing nanoparticles
US20060211004A1 (en) 2005-02-15 2006-09-21 Ilsley Diane D Methods and compositions for determining non-specific cytotoxicity of a transfection agent
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
EP1906826A4 (de) 2005-07-22 2009-10-21 Tomotherapy Inc System und verfahren zur erfassung einer atemphase eines patienten in strahlungstherapie
CA2616136A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of evaluating dose delivered by a radiation therapy system
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
CN101267857A (zh) 2005-07-22 2008-09-17 断层放疗公司 对移动的关注区实施放射疗法的系统和方法
CA2616292A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treament plan
CN101267767A (zh) 2005-07-23 2008-09-17 断层放疗公司 使用机架和治疗床的协同运动的放射疗法成像和实施
US8945508B2 (en) * 2009-10-13 2015-02-03 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
NZ598419A (en) * 2009-10-16 2013-11-29 Dow Agrosciences Llc Use of dendrimer nanotechnology for delivery of biomolecules into plant cells
CN103052713A (zh) * 2010-07-07 2013-04-17 陶氏益农公司 官能化线性dna盒的生成及植物中量子点/纳米颗粒介导的投递
WO2014030147A2 (en) * 2012-08-23 2014-02-27 Fundación Fraunhofer Chile Research Synthetic proteins based on dendrimers
EP2962309B1 (de) 2013-02-26 2022-02-16 Accuray, Inc. Elektromagnetisch betätigter mehrblatt-kollimator
JP6523252B2 (ja) * 2013-05-02 2019-05-29 テラ‐バリア フィルムズ プライベート リミテッド デンドリマーでカプセル化されたナノ粒子を含むカプセル化バリアスタック
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2019103857A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
CR20200251A (es) 2017-11-17 2020-07-17 Iovance Biotherapeutics Inc Expansión de til de aspirados con aguja fina y biopsias por punción
BR112020013848A2 (pt) 2018-01-08 2020-12-01 Iovance Biotherapeutics, Inc. métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
BR112020021660A2 (pt) 2018-04-27 2021-02-02 Iovance Biotherapeutics, Inc. métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, composição de criopreservação
KR20210099573A (ko) 2018-11-05 2021-08-12 이오반스 바이오테라퓨틱스, 인크. 개선된 종양 반응성 t-세포의 선택
TW202039830A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
BR112021008549A2 (pt) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
EP3877511A1 (de) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Expansion von tils unter verwendung von akt-signalweg-inhibitoren
AU2019392748A1 (en) 2018-12-05 2021-06-10 Fred Hutchinson Cancer Center Reduced and minimal manipulation manufacturing of genetically-modified cells
US20220193131A1 (en) 2018-12-19 2022-06-23 Iovance Biotherapeutics, Inc. Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
SG11202109331QA (en) 2019-03-01 2021-09-29 Iovance Biotherapeutics Inc Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
JP2022553389A (ja) 2019-10-25 2022-12-22 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
CA3161104A1 (en) 2019-12-11 2021-06-17 Cecile Chartier-Courtaud Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
CA3177413A1 (en) 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection of improved tumor reactive t-cells
TW202208617A (zh) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 用於產生腫瘤浸潤性淋巴球的過程及其在免疫療法中的用途
EP4225330A1 (de) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Behandlung von nsclc-patienten mit tumorinfiltrierenden lymphozytentherapien
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CA3201818A1 (en) 2020-12-11 2022-06-16 Maria Fardis Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
JP2024500403A (ja) 2020-12-17 2024-01-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球によるがんの治療
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
TW202304480A (zh) 2021-03-19 2023-02-01 美商艾歐凡斯生物治療公司 腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法
CN118019546A (zh) 2021-03-23 2024-05-10 艾欧凡斯生物治疗公司 肿瘤浸润淋巴细胞的cish基因编辑及其在免疫疗法中的用途
IL307800A (en) 2021-04-19 2023-12-01 Iovance Biotherapeutics Inc Chimeric costimulatory receptors, chemokine receptors and their use in cellular immunotherapy
WO2022245754A1 (en) 2021-05-17 2022-11-24 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2023004074A2 (en) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
AU2022343729A1 (en) 2021-09-09 2024-03-21 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
AU2022388729A1 (en) 2021-11-10 2024-05-16 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023220608A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024055017A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024055018A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024098027A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5527524A (en) * 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
JPH08510639A (ja) * 1993-04-19 1996-11-12 メディソーブ・テクノロジーズ・インターナショナル・リミテッド・パートナーシップ 細胞取込みと遺伝子発現の促進と標的化をもたらす接合体と核酸のカプセル化
GB9317380D0 (en) * 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
DE69529495T2 (de) * 1994-01-21 2003-06-12 Powderject Vaccines Inc Gasbetätigtes element zum austragen von genmaterial
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
KR100357839B1 (ko) * 1994-03-07 2003-08-02 더 다우 케미칼 캄파니 생체활성및/또는표적화된덴드리머콘쥬게이트
NL9401886A (nl) * 1994-05-27 1996-01-02 Dsm Nv Samenstelling bestaande uit een dendrimeer en een in het dendrimeer opgesloten actieve stof, een werkwijze voor de bereiding van een dergelijke samenstelling en een werkwijze voor het vrijgeven van de actieve stof.
GB9425600D0 (en) * 1994-12-19 1995-02-15 Medical Res Council Targeting complexes and use thereof
US5919442A (en) * 1995-08-11 1999-07-06 Dendritech, Inc. Hyper comb-branched polymer conjugates
DE19622628A1 (de) * 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Stabilisierung von Metallkonjugaten

Also Published As

Publication number Publication date
US6475994B2 (en) 2002-11-05
JP2002500033A (ja) 2002-01-08
CA2317666A1 (en) 1999-07-15
EP1051244B1 (de) 2007-06-27
EP1051244A4 (de) 2003-06-11
EP1051244A1 (de) 2000-11-15
WO1999034908A1 (en) 1999-07-15
US20020013283A1 (en) 2002-01-31
DE69936377D1 (de) 2007-08-09

Similar Documents

Publication Publication Date Title
DE69936377D1 (de) Verfahren und produkt zur transfektion mit genetischem material
Mout et al. Direct cytosolic delivery of CRISPR/Cas9-ribonucleoprotein for efficient gene editing
Choi et al. Enhanced transfection efficiency of PAMAM dendrimer by surface modification with L-arginine
Asayama et al. Synthesis of novel polyampholyte comb-type copolymers consisting of a poly (L-lysine) backbone and hyaluronic acid side chains for a DNA carrier
Segura et al. Substrate-mediated DNA delivery: role of the cationic polymer structure and extent of modification
Tan et al. Block polymer micelles enable CRISPR/Cas9 ribonucleoprotein delivery: physicochemical properties affect packaging mechanisms and gene editing efficiency
Boussif et al. Synthesis of polyallylamine derivatives and their use as gene transfer vectors in vitro
Cook et al. Galactosylated polyethylenimine-graft-poly (vinyl pyrrolidone) as a hepatocyte-targeting gene carrier
Kim et al. Synthesis of biodegradable cross-linked poly (β-amino ester) for gene delivery and its modification, inducing enhanced transfection efficiency and stepwise degradation
WO2003093469A3 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
Rui et al. Reducible branched ester-amine quadpolymers (rBEAQs) codelivering plasmid DNA and RNA oligonucleotides enable CRISPR/Cas9 genome editing
Pichon et al. Poly [Lys-(AEDTP)]: a cationic polymer that allows dissociation of pDNA/cationic polymer complexes in a reductive medium and enhances polyfection
IL305044A (en) New CRISPR enzymes and systems
DE50006269D1 (de) Kombinationen zur einführung von nucleinsäuren in zellen
WO1998041648A3 (en) Target genes for allele-specific drugs
Kumar et al. Combinatorial polycation synthesis and causal machine learning reveal divergent polymer design rules for effective pDNA and ribonucleoprotein delivery
PT842289E (pt) Recombinacao homologa em celulas eucariotas com inactivacao do sistema de reparacao de emparelhamentos incorrectos
US20190233820A1 (en) Nanoparticles functionalized with gene editing tools and related methods
Green et al. Catch and release: photocleavable cationic diblock copolymers as a potential platform for nucleic acid delivery
Okuda et al. Cytosolic soluble proteins induce DNA release from DNA–gene carrier complexes
Zheng et al. Transfection of cells mediated by biodegradable polymer materials with surface‐bound polyethyleneimine
Egorova et al. Development of a receptor‐targeted gene delivery system using CXCR4 ligand‐conjugated cross‐linking peptides
Blocker et al. Surface immobilization of plasmid DNA with a cell-responsive tether for substrate-mediated gene delivery
Kichler et al. Polyethylenimines: a family of potent polymers for nucleic acid delivery
WO2001023541A3 (en) Compositions and methods for altering gene expression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties